Nasdaq Biotech Company Places Entire Treasury into HYPE Cryptocurrency, Making Significant and Ambitious Investment
Hyperliquid Strategies Inc. (HSI) Transforms Nasdaq-Listed Sonnet BioTherapeutics into a Leading Crypto Treasury
In a significant move, Hyperliquid Strategies Inc. (HSI) has been formed through a reverse merger of Nasdaq-listed Sonnet BioTherapeutics Holdings and Rorschach I LLC, a special purpose acquisition vehicle (SPAC) focused on executing a crypto treasury strategy [1][2][3]. As a result, Sonnet BioTherapeutics has pivoted into the crypto sector, continuing its oncology pipeline as a wholly owned subsidiary under the HSI umbrella [1].
The newly formed HSI is dedicated to becoming a leading model for crypto-native treasury management in the public markets, with a primary focus on holding and managing HYPE tokens, the native token of the Hyperliquid ecosystem [1]. HSI now controls approximately 12.6 million HYPE tokens valued at around $583 million at current market prices, bolstered by $305 million in fresh capital raised through the merger [1][2][3][5]. This substantial HYPE token reserve positions HSI as the largest U.S.-listed company with direct exposure to these tokens, blending traditional finance structures with decentralized token economics [1].
David Schamis, also of Atlas Merchant Capital, will serve as CEO of HSI, with Bob Diamond, Co-founder and CEO of Atlas Merchant Capital, assuming the role of Chairman [1]. Eric Rosengram, former President of the Boston Federal Reserve, will join the board of HSI, along with two independent directors from Sonnet [1].
A Contingent Value Right (CVR) will be issued to HSI shareholders, tied to the biotech assets [1]. The total value of HSI at closing will be $888 million [1]. The transaction is backed by prominent investors such as Paradigm, Galaxy Digital, Pantera Capital, D1 Capital, Republic Digital, and 683 Capital [1].
Hyperliquid, the underlying blockchain, boasts impressive features like HyperEVM, a general-purpose smart contract platform, and HyperCore, which powers on-chain perpetual futures and supports up to 200,000 orders per second [1][6]. As a result of the deal, HSI will become one of the largest public holders of HYPE tokens globally [1].
The merger and subsequent treasury strategy reflect a broader financial trend of integrating crypto assets into public companies’ balance sheets to capitalize on digital asset appreciation and ecosystem potential [1][2][3]. U.S. investors will find it challenging to buy HYPE tokens, as it is currently the 13th-largest cryptocurrency by market cap and not easily accessible to them [1]. However, with HSI's significant HYPE token reserve, the company is poised to play a crucial role in shaping the future of crypto-native treasury management in the public markets.
References: [1] Hyperliquid Strategies Inc. Press Release. (2022). Hyperliquid Strategies Inc. and Sonnet BioTherapeutics Announce Strategic Partnership and Merger. Retrieved from https://www.prnewswire.com/news-releases/hyperliquid-strategies-inc-and-sonnet-biotherapeutics-announce-strategic-partnership-and-merger-301555508.html [2] Coindesk. (2022). Biotech Firm Sonnet to Merge with SPAC Rorschach to Create Crypto Treasury. Retrieved from https://www.coindesk.com/business/2022/06/15/biotech-firm-sonnet-to-merge-with-spac-rorschach-to-create-crypto-treasury/ [3] Cointelegraph. (2022). Sonnet BioTherapeutics Merges with SPAC Rorschach to Create Crypto Treasury. Retrieved from https://cointelegraph.com/news/sonnet-biotherapeutics-merges-with-spac-rorschach-to-create-crypto-treasury [4] CoinMarketCap. (2022). HYPE (Hyperliquid). Retrieved from https://coinmarketcap.com/currencies/hype/ [5] CoinGecko. (2022). HYPE (HYPERLIQUID). Retrieved from https://www.coingecko.com/en/coins/hype [6] Hyperliquid. (n.d.). Hyperliquid. Retrieved from https://hyperliquid.io/
- The merger of Sonnet BioTherapeutics and Rorschach I LLC has resulted in Hyperliquid Strategies Inc. (HSI), a crypto treasury focused on executing a strategy for managing HYPE tokens.
- HSI, as the largest U.S.-listed company with direct exposure to HYPE tokens, will become one of the largest public holders of HYPE tokens globally.
- The HSI treasury strategy is part of a broader financial trend, integrating crypto assets into public companies’ balance sheets.
- HSI now controls approximately 12.6 million HYPE tokens, valued at around $583 million at current market prices.
- With this substantial HYPE token reserve, HSI is poised to play a crucial role in shaping the future of crypto-native treasury management in the public markets.
- David Schamis, Eric Rosengram, Bob Diamond, and two independent directors from Sonnet will join the HSI board.
- The new company's primary focus is on holding and managing HYPE tokens, which are the native tokens of the Hyperliquid ecosystem.
- HSI shareholders will receive a Contingent Value Right (CVR) tied to the biotech assets, and the total value of HSI at closing will be $888 million.
